ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Risk of drug eruption associated with the use of tetracyclines, macrolides, and fluoroquinolones: real-world evidence from a pharmacovigilance study utilizing the FDA adverse event reporting system.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, concerns regarding the risk of drug eruption associated with the use of tetracyclines were raised by the United States Food and Drug Administration (U.S. FDA). Therefore, it is necessary to reevaluate this risk. This study aimed to quantify the signal of drug eruption associated with the use of tetracyclines. Also, the signal of drug eruption with the use of two other antimicrobial drugs-macrolides and fluoroquinolones-was investigated for comparison. A pharmacovigilance case/noncase study was conducted using the U.S. FDA Adverse Event Reporting System (FAERS). Reports of drug eruptions using the preferred term were retrieved from the database from 2020-2025 quarter 1. The associations between the risk of drug eruption and the three antibiotic classes were quantified using disproportionality analysis utilizing both Bayesian and traditional statistical analyses, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayes geometric mean (EBGM) and information component (IC). All three antibiotic classes were significantly associated with the risk of drug eruption. However, compared with fluoroquinolones and macrolides, tetracyclines were more strongly associated with drug eruption. Disproportionality analysis revealed that the ROR for tetracycline was 6.65 (95% confidence interval (CI), 4.00-11.09) in 2020; in 2024, it was 30.75 (95% CI, 24.46-38.67). For macrolides, the RORs were 2.16 (95% CI, 1.20-3.92) and 10.12 (95% CI, 7.16-14.31) in 2020 and 2024, respectively. The RORs for fluoroquinolones were 4.57 (95% CI, 3.20-6.52) in 2020 and 2.27 (95% CI, 1.31-3.92) in 2024. Males were predominant in the tetracycline group (74%), and females were predominant in the macrolide group (56%). Approximately 41% and 40% of patients in the fluoroquinolone and macrolide classes, respectively, were hospitalized. All three antibiotic classes were associated with the signal of drug eruption. The signal of drug eruption occurred across all age groups with all three antibiotics. Also, the signal has affected both males and females across the years studied. However, there is no specific pattern for the signal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.